Cohance Appoints Yann D’Herve as New CEO
D’Herve has succeeded Dr. Singh, bringing a wealth of industry experience to the position, having previously served in senior positions at Evonik.
Hyderabad-based Integrated CDMO, Cohance Lifesciences, has announced the appointment of Yann D’Herve as its new CEO (1). D’Herve has taken over the role from Dr. Sudhir Kumar Singh, effective from August 1, 2025.
Prior to his new role at Cohance, D’Herve served as the Senior Vice President and General Manager for the Healthcare division of Evonik. In this previous role, D’Herve had full profit and loss accountability, including for the company’s CDMO business, and was responsible for 2,600 employees across nine manufacturing sites (1).
“I am excited to join a growing CDMO with differentiated technologies such as ADCs [antibody drug conjugates] and oligonucleotides and a strong global asset base,” said D’Herve in the company press release (1). “I look forward to working with the Cohance team to support the development and manufacturing of life-saving drugs for our partners.”
D'Herve has an MBA from Université de Picardie Jules Verne in Amiens, and a master’s in chemistry from CPE, Lyon, France. He started his career in manufacturing, gaining practical experience across production and operations.
“We are delighted to welcome Yann to Cohance,” added Vivek Sharma, Executive Chairman of Cohance Lifesciences, in a company press release (1). “His deep experience in leading multifaceted global pharmaceutical services businesses will be of tremendous benefit in accelerating the growth of our CDMO platform.”
In May 2025, Suven Pharmaceuticals underwent a rebrand to become Cohance Lifesciences. According to the company, the rebrand marked an important step forward in its evolution into a specialized technology driven global CDMO platform (2).
“The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market,” commented Sharma in a press release about the rebrand (2). “We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world.”
Capturing the company’s commitment to collaborate with global investors and enhance in their molecules and products, the new name of Cohance has been approved by the Ministry of Corporate Affairs, Government of India. Additionally, the company made the necessary application to the BSE Limited and the National Stock Exchange to ensure the new company name replaced the old one in each instance of its appearance in the Memorandum of Association and the Articles of Association (2).
References
1. Cohance Lifesciences. Cohance Lifesciences Appoints Yann D’Herve as CEO of CDMO Business, Effective August 1, 2025. Press Release, July 28, 2025.
2. Cohance Lifesciences. Cohance Lifesciences, the New Identity of Suven Pharmaceuticals. Press Release, May 7, 2025.